Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s technology in two candidates. The Czech biotech disclosed the update on the ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs). Ivonescimab remains the ...

Readers hoping to buy Parkland Corporation ( TSE:PKI ) for its dividend will need to make their move shortly, as the... Parkland Corporation ("Parkland" or the "Company") (TSX: PKI) today is ...

Antibody-drug conjugates (ADCs) were associated with a higher risk for all-grade adverse events (AEs) in metastatic breast cancer than standard therapy, according to a meta-analysis. However ...

located in 49 states and containing approximately 47.2 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol "ADC".

The ODT-ADS-7B64G-3 is an ultra-high-bandwidth time-interleaved ADC designed in a 3nm CMOS process. This 7-bit, 64GSPS ADC supports ac-coupled input signals up to Nyquist and features a full-scale ...

CrossBridge Bio’s innovative approach to create stable, multi-loaded antibody–drug conjugates is set to generate a suite of first-in-class and best-in-class cancer therapies. Antibody–drug ...

The deal – with a potential value of $180 million – is focusing on ORM-6151, which combines the properties of ADCs and protein degraders, another emerging therapeutic category in oncology.